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Abstract
Light chain (AL) amyloidosis is a plasma cell dyscrasia characterized by the pathologic production of fibrillar
proteins comprised of monoclonal light chains which deposit in tissues and cause organ dysfunction. The
diagnosis can be challenging, requiring a biopsy and often specialized testing to confirm the subtype of systemic
disease. The goal of treatment is eradication of the monoclonal plasma cell population and suppression of the
pathologic light chains which can result in organ improvement and extend patient survival. Standard treatment
approaches include high dose melphalan (HDM) followed by autologous hematopoietic stem cell transplantation
(SCT) or oral melphalan with dexamethasone (MDex). The use of novel agents (thalidomide, lenalidomide and
bortezomib) alone and in combination with steroids and alkylating agents has shown efficacy and continues to be
explored. A risk adapted approach to SCT followed by novel agents as consolidation reduces treatment related
mortality with promising outcomes. Immunotherapeutic approaches targeting pathologic plasma cells and amyloid
precursor proteins or fibrils are being developed. Referral of patients to specialized centers focusing on AL
amyloidosis and conducting clinical trials is essential to improving patient outcomes.
Introduction
Primary systemic or light chain amyloidosis (AL) is
characterized by a clonal population of plasma cells in
the bone marrow that produce monoclonal light chain
of kappa or lambda type. Amyloidogenic light chains
misfold forming a highly ordered beta pleated sheet con-
figuration which is the structure that defines amyloid
fibrils of any type (including light chain, hereditary,
senile systemic or secondary). Contiguous beta pleated
sheets wind together into a fibrillar configuration
instead of the typical alpha helical pattern of most pro-
teins [1]. Amyloid fibrils deposit in organs, progressively
interfering with organ structure and function [2-4].
Commonly affected organs include the heart, kidneys,
gastrointestinal (GI) tract/liver or the peripheral or auto-
nomic nervous system (NS).
AL amyloidosis should be suspected in any patient
with a monoclonal gammopathy and unexplained short-
ness of breath, fatigue, edema, weight loss, orthostasis or
paresthesias (Table 1)[5]. However, it often requires an
astute clinician because symptoms are diverse and easily
mimicked by more common disorders. Once considered,
the evaluation for AL amyloidosis includes testing to
identify an underlying clonal plasma cell disorder (bone
marrow aspirate/biopsy, serum and urine electrophor-
eses and immunofixation and serum free light chain
testing). In addition, it is essential to determine organs
of involvement and an initial work up should include
echocardiogram, EKG, 24 hour urine total protein
assessment, orthostatic blood pressures; specific GI and
NS testing should be performed if indicated. Confirma-
tion of amyloidosis requires tissue sampling to demon-
strate congophilic amyloid deposits or fibrils that are 7-
10 nanometers in diameter by electron microscopy.
While in some patients amyloid deposition will be iden-
tified on bone marrow biopsy, in combination with fat
pad aspirate, amyloid deposition can be demonstrated in
85% of patients [6]. However, because there remains a
15% chance that amyloidosis is present even when both
the bone marrow and fat pad are negative, involved
organs should be biopsied if the index of suspicion is
high.
Although AL amyloidosis is the most common form
of systemic amyloidosis, up to 10% of patients may pre-
sent with “secondary” or “hereditary” amyloidosis and
an incidental monoclonal gammopathy of undetermined
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amyloid fibrils regardless of their protein of origin inter-
calate Congo red stain, demonstrate apple-green bire-
fringence under light microscopy and have similar
ultrastructural characteristics by electron microscopy. In
any patient with more than one source of amyloid, it is
essential to determine with certainty the protein compo-
sition of the amyloid deposit which may be amyloid A
or transthyretin in secondary or hereditary amyloid,
respectively. Immunohistochemistry, while routinely
used to type amyloid deposits is often unreliable [8,9].
Immunogold electron microscopy is more specific than
immunohistochemistry and can be performed on a fat
pad samples if amyloid is present and the appropriate
antibodies are available [10,11]. However, using laser
microdissection with mass spectrometry, all known
types of amyloid can be identified with a single test and
this method is most reliable [12]. However, this technol-
ogy is only available at specialized centers. Treatment
for AL systemic amyloidosis which is distinctly different
from therapy for hereditary variants or secondary amy-
loidosis, should only be considered once the precursor
protein is identified with certainty.
In the absence of clonal plasma cells in the bone mar-
row, light chain amyloid may localized to a single site,
most often the skin, larynx or urinary tract [13]. Isolated
pulmonary nodules and colonic polyps may represent
localized rather than systemic disease [14]. Localized
amyloidosis does not require systemic therapy and
symptoms should be managed by system specific specia-
lists. An algorithm for the work up of a patient once
amyloid is identified by biopsy is shown (Figure 1).
T h es o u r c eo ft h ea m y l o i d o g e n i cl i g h tc h a i n si sa
clone of plasma cells, histologically identical to those
seen in the more common plasma cell dyscrasia, multi-
ple myeloma. Given these similarities, to date, treat-
ments for AL have been largely derived from those
studied for the treatment of multiple myeloma. How-
ever, amyloid- specific research is urgently needed
because patients with AL amyloidosis often do not toler-
ate therapy at doses used for patients with multiple
myeloma due to amyloid-affected organ dysfunction. At
the present time, there are no drugs specifically FDA-
approved for the treatment of amyloidosis.
Goals of Therapy and Prognostic Markers
Current therapies that are available for AL amyloidosis
are aimed at eradicating the pathologic plasma cells and
eliminating the circulating free light chain. Interruption
of precursor protein production can lead to the regres-
sion of amyloid deposits, organ improvement and
extended survival [15-17]. The efficacy of a treatment
can be measured both in terms of reduction in the bur-
den of clonal plasma cell disease (hematologic response)
and by improvement in the organ function (organ
response)[18]. The serum free light chain (FLC) assay
which detects circulating FLCs rather than intact immu-
noglobulins, is a more powerful predictor of survival in
AL amyloidosis than standard immunoelectrophoresis
[19]. In 2010, the International Society for Amyloidosis
revised and validated hematologic response criterion for
AL amyloidosis based on FLC assessment at baseline
and following treatment (Figure 2)[20]. While complete
response (CR) continues to require a negative serum
and urine immunofixation electrophoresis (IFE), normal
serum FLC ratio and < 5% clonal plasma cells on bone
marrow studies, the definitions of partial response (PR)
and very good partial response (VGPR) are based on the
difference between involved and uninvolved FLC
(dFLC). Because ≥ VGPR, defined as dFLC < 40 mg/L is
associated with an 80% OS at 3 years, clinicians should
adapt therapy in patients who fail to achieve this goal.
Cardiac biomarkers were studied in AL amyloidosis
because the extent of cardiac involvement may be the
most important determinant of outcome. Troponin I or
T provide a quantitative assessment of cardiac damage
and BNP and/or NT-proBNP indicate cardiomyocyte
stress and are independently associated with survival
[ 2 1 ] .B yu s i n gt h e s eb i o m a r k e r s ,as t a g i n gs y s t e mh a s
been developed has been developed and patients can be
classified as having stage I, II or III disease with survi-
vals of 26, 11 and 3.5 months, respectively [22]. This
staging system is important for clinical management,
but also for stratifying patients enrolled on clinical trials.
Therapeutic options in AL Amyloidosis
High-dose melphalan and autologous stem cell transplant
The first effective treatment for AL amyloidosis was oral
melphalan and prednisone. However, only a quarter of
patients achieved a hematologic response (ORR; PR, CR)
to this treatment and the median survival was only 12-
Table 1 Reasons to Suspect AL Amyloidosis
1. Non-diabetic nephrotic syndrome
2. Non-ischemic cardiomyopathy and hypertrophy*
3. Hepatomegaly or increased alkaline phosphatase**
4. Monoclonal gammopathy with
a. Autonomic or sensory neuropathy
b. Unexplained fatigue
c. Edema
d. Unintentional weight loss
Signs and symptoms that may represent AL amyloidosis in a patient. Non-
diabetic nephrotic syndrome; non-ischemic cardiomyopathy and hypertrophy
on echocardiogram, especially in the absence of hypertension*; hepatomegaly
or increased alkaline phosphatase with no liver abnormalities by imaging**; or
autonomic neuropathy with orthostasis or sensory neuropathy with a
monoclonal protein. In patients with monoclonal gammopathy and
unexplained fatigue, edema, weight loss or paresthesias, AL amyloidosis
should also be considered.
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logous stem cell transplantation (HDM/SCT) was
explored in AL amyloidosis based on its success in
treating multiple myeloma. A pilot study of five patients
conducted at Boston University was published in 1996
and demonstrated the safety and efficacy of this
approach [24]. The phase II study (N = 25) was subse-
quently reported and demonstrated a complete hemato-
logic response in 62% (13/21) of evaluable patients and
organ improvement in 65% of patients [25].
Although HDM/SCT effectively reduces clonal disease
and circulating light chains in patients with AL amyloi-
dosis, the toxicity of this approach must be appreciated.
The average treatment related mortality (TRM) in four
single center studies is 21% but has been reported as
high as 39%[26]. Patients with cardiac involvement and
autonomic dysfunction are particularly susceptible to
fluid shifts and hypotension as the result of high-dose
G-CSF and must be monitored during all phases of
treatment including mobilization/collection. Patients
with cardiac amyloid can experience critical arrhythmias
or sudden death during stem cell infusion presumably
related to the toxicity of the DMSO preservative. Wash-
ing the cells prior to infusion may reduce this risk and
is a common practice at some centers. Cardiac staging
has helped to minimize TRM by identifying patients
susceptible to complications of HDM/SCT [27,28]. With
careful patient selection and vigilant attention to sup-
portive strategies, HDM/SCT can be safe but should
only be performed at experienced centers.
Two large studies from experienced centers confirmed
the utility of HDM/SCT as a treatment for AL amyloi-
dosis. At Boston University, 312 patients with AL amy-
loidosis were treated with HDM/SCT at 200 mg/m
2 or
140 mg/m
2 based on age and cardiac status. Utilizing a
multidisciplinary team for peri-transplant management,
TRM was reduced to 14% in these selected patients
[16]. In this series, the median survival for those who
achieved CR was more than 10 years compared to 50
months for those who did not achieve CR [29]. A sec-
ond large patient series from the Mayo Clinic reported
434 patients with AL amyloidosis treated with HDM/
Evaluate for a monoclonal gammopathy 
a) Bone marrow aspirate & biopsy 
b) SPEP & IFE; UPEP & IFE 
c) Quantitative Ig measurement 
d) Serum FLC assessment  
Monoclonal Gammopathy Present 
Likely AL amyloidosis 
Evaluate for Systemic Disease and Organ Involvement 
Renal:    Creatinine; 24 hour urine total protein  
Cardiac:  EKG; Echocardiogram; Troponin; BNP (NT-ProBNP) 
GI/Hepatic:  Alkaline phosphatase; Liver Ultrasound*; Endoscopy*  
Nerve:  Orthostatics; Nerve conduction studies*; Gastric emptying*  
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Ɲ : Most likely transthyretin (TTR) mutation but consider other hereditary forms
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Figure 1 Evaluation following tissue diagnosis of amyloid.
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in 76% of patients including 39% who achieved CR.
Treatment related mortality was 10%[6]. As seen in the
Boston series, the strongest predictor of outcome was
hematologic CR. The median survival was not reached
for those who achieved CR, compared to 107 months
for those with PR and 32 months for those with no
response (p < 0.001)[6].
At Memorial Sloan-Kettering Cancer Center, risk-
adapted chemotherapy dosing has been combined with
post transplant consolidation in an effort to minimize
toxicity and maintain efficacy [30]. In a series of trials,
patients with newly diagnosed AL amyloidosis were
treated with melphalan 100, 140 or 200 mg/m
2 based on
age, renal function and cardiac involvement. Patients
with persistent clonal disease following SCT received
consolidation, either thalidomide and dexamethasone or
bortezomib and dexamethasone, in sequential studies.
The low TRM (4% and 11% respectively) in both trials
suggests that this approach is safe. With thalidomide-
based consolidation, the overall response rate at 12
months was 71% (including 36% CR)[31]; and was 96%
(65% CR) when bortezomib-based therapy was used
[32]. Organ improvement one year post transplant was
noted in 44% and 60% of patients with thalidomide and
bortezomib-based consolidation, respectively [31,33].
Notably, organ function continued to improve over time
and increased from 60% to 88% at 24 months after SCT
in the latter study [34].
Despite the reported efficacy, the use of HDM/SCT in
AL amyloidosis remains controversial. A pivotal trial
highlighting this controversy was reported by the Inter-
groupe Francophone du Myeloma (IFM) in 2007 [35].
Among 29 centers, 100 patients were randomized to
either conventional chemotherapy using oral melphalan
and dexamethasone or HDM/SCT. Although
hematologic response rates were similar (68% vs. 67%)
in both treatment groups; at three years of follow up,
the median OS was superior in the conventional che-
motherapy arm (57 vs. 22 months; P = 0.04)[35]. Treat-
ment related mortality was unusually high (24%) in the
first 100 days following HDM/SCT suggesting that
patients may not have been suitable candidates for
transplant. In addition, the study was performed at mul-
tiple centers, some with very limited experience in car-
ing for patients with amyloidosis. A landmark analysis
examining only patients alive six months post treatment
showed no difference in the overall survival between the
two groups (P = 0.38) leading the authors to conclude
that there is no benefit of HDM/SCT over conventional
chemotherapy. However, with almost 20% of patients
excluded from this analysis (9 in the SCT arm) in addi-
tion to 13 patients who never received the prescribed
HDM (10 died, and 3 others excluded), the number of
evaluable patients who underwent SCT is small and
insufficient to suggest HDM/SCT should be abandoned.
Non-transplant approaches
While HDM/SCT is an effective way of achieving rapid,
hematologic responses, only 20-25% of patients present-
ing with AL amyloidosis are eligible for such aggressive
treatment [6]. Strategies for those not eligible for trans-
plantation have largely been alkylator-based oral regi-
mens but have now may include novel agents such as
immunomodulatory drugs or proteasome inhibitors.
Melphalan and prednisone became the standard of
care when superior outcomes were demonstrated as
compared to colchicine [23]. Although objective
responses could be demonstrated, these were often
delayed (median time to response close to 1 year), and
only seen in the minority of patients (< 30%). Because
responses are slow, organ progression may occur during
the initial months of therapy. In patients who remain
clinically stable, it is often difficult to know if a patient
is destined to fail alkylator based therapy or whether it
is too early to abandon the approach. Despite these lim-
itations, alkylating agents can be useful in patients ineli-
gible for aggressive therapy. Even patients with severe
cardiac involvement may benefit from continuous, daily,
oral melphalan as a palliative measure [36].
Although high-dose dexamethasone regimens acceler-
ate response times in patients with AL amyloidosis, the
usual schedule of dexamathasone (40 mg on days 1-4,
9-12, 17-20) is toxic for these patients [37]. A modified
schedule of dexamethasone (40 mg days 1-4) was devel-
oped and response rates are promising when used in
combination with melphalan. In 46 patients treated with
oral melphalan and high dose dexamethasone (MDex),
31 (67%) achieved a hematologic response and 15 (33%)
achieved a complete response. Twenty-two (48%)
Figure 2 Survival in patients with AL amyloidosis by
hematologic response (adapted with permission from Dr.
Pallidini) [20].
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w i t ham e d i a nt i m et or e s p o n s eo f4 . 5m o n t h s .T h ed a y
100 mortality was only 4% and adverse effects were seen
in 11% of patients [38]. An update of this study showed
the median progression free and overall survival was 3.8
and 5.1 years, respectively [39]. Similar to high dose
chemotherapy, the survival was longer for patients who
responded to therapy (median not reached) compared to
those who did not respond (2.1 years)[39]. Subsequent
studies confirmed the activity of this regimen, although
outcomes for patients with advanced cardiac disease
remain poor with a median overall survival of 10.5
months [40]. Current studies seek to improve the effi-
cacy of oral melphalan and dexamethasone by adding a
third agent (such as thalidomide, lenalidomide or borte-
zomib) to this combination [41-43]. The combination of
bortezomib, melphalan and dexamethasone (BMDex) is
being compared in a randomized fashion to standard
MDex as upfront treatment for patients with AL amyloi-
d o s i sw h oa r ei n e l i g i b l eo rr e f u s eS C T .T w od i s t i n c t
alkylating agents, cyclophosphamide and bendamustine,
in combination with corticosteroids and novel agents
are also being investigated.
Novel agents
Thalidomide was the first novel agent explored for AL
amyloidosis due to its efficacy in multiple myeloma. A
phase I/II dose escalation trial using thalidomide in
patients previously treated with melphalan and dexa-
methasone found the agent to have activity but with sig-
nificant toxicity and the starting dose in AL amyloidosis
should be no higher than 50 mg [44]. Lenalidomide, a
second generation immunomodulatory (IMID) agent,
has been combined with dexamethasone for the treat-
ment of AL amyloidosis. Hematologic response rates
were 67% in a phase II trial and were associated with
organ responses [45]. The median time to response was
6 cycles (range, 3 to 6). A reduced dose of 15 mg/day
was better tolerated than the daily dose of 25 mg/day
used in multiple myeloma. Side effects include cytope-
nias, rash, fatigue, muscle cramping and venous throm-
bosis. Patients require anti-thrombotic prophylaxis
similar to patients with multiple myeloma [46]. Phase I/
II studies combining lenalidomide and dexamethasone
with either melphalan or cyclophosphamide are ongoing
but myelosuppression may be limiting [41]. Pomalido-
mide, the newest IMID being investigated clinically, was
associated with a 47% response rate in extensively pre-
treated patients with AL amyloidosis [47]. Severe
adverse events ≥ grade 3 were seen in 56% of patients
with neutropenia being most common. Increases in
BNP/NT-proBNP with Imid-based regimens were initi-
ally concerning for cardiac decompensation and led to
early discontinuation of therapy. It remains unclear
whether this elevation represents true cardiac toxicity,
fluid retention or is entirely clinically insignificant. How-
ever, it makes assessing organ response very challenging.
Targeting the proteasome, the cellular machinery lar-
gely responsible for protein homeostasis was rational
based on the misfolded nature of proteins in AL amyloi-
dosis. Bortezomib, a reversible inhibitor of the 26S pro-
teasome has been studied in a phase I/II dose escalation
trial as a single agent. Doses up to 1.6 mg/m
2 weekly
and 1.3 mg/m
2 on a biweekly schedule were well toler-
ated in patients with relapsed disease [48]. Seventy
patients were treated on the phase II portion, the major-
ity on the biweekly schedule with responses seen in 67%
of patients [49] illustrating the single agent activity of
bortezomib in AL amyloidosis. The time to first
response was rapid (1.2 months) with a median time to
CR of 2.3 months [48]. Overall treatment was safe with
peripheral neuropathy seen in 45% of patients [48].
When 1.3 mg/m
2 biweekly was used in combination
with dexamethasone, patients with relapsed disease (N =
7) or those ineligible for HDM/SCT (N = 11) had a 94%
response rate including a 44% CR. Organ improvement
occurred in 28% of patients. Again, hematologic
responses were rapid (< 1 month) as was time to organ
improvement (4 months). Neurotoxicity occurred in
67% of patients but was > grade 2 in only 7%. Dexa-
methasone toxicity was transient and manageable and
the main reason for discontinuation of treatment was
adverse effects from bortezomib in 44% of patients [50].
Bortezomib has been combined with oral melphalan
and dexamethasone (BMDex) to treat AL amyloidosis
with promising response frequency (83%) in untreated
(N = 13) and relapsed (N = 17) patients [42,43]. The
randomized trials comparing BMDex to standard MDex
are currently enrolling in the United States and in Eur-
ope and have the potential to change the standard of
care for newly diagnosed AL amyloid patients. Cyclo-
phosphamide, bortezomib and dexamethasone (CyBor-
D) also demonstrates significant activity in AL amyloi-
dosis with hematologic responses in 93% of untreated
(N = 8) and relapsed (N = 7)patients [51]. Second and
third generation proteasome inhibitors are in earlier
stages of development including carfilzomib, an irrever-
sible proteasome inhibitor with known activity in multi-
ple myeloma and the orally bioavailable agent
MLN9708.
Immunotherapy
The notion that amyloid deposits persist due to their
recognition as “self’’ by the immune system, protected
from effective immune attack, has led to strategies that
harness the immune system to target amyloid deposits
directly, the precursor amyloid-forming protein or alter-
n a t e l yt h ep a t h o l o g i cp l a s m ac e l l .A m y l o i df i b r i l s ,
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proteins including serum amyloid P (SAP), a calcium-
dependent glycoprotein universally concentrated in amy-
loid deposits [13]. Because SAP stabilizes amyloid fibrils
and promotes fibrillogenesis, SAP was considered a
potential therapeutic target and several strategies have
emerged. A novel compound, CPHPC ((R) -1-[6-[(R)-2-
Carboxy-pyrrolidin-1yl]-6-oxo-hexanoyl] pyrrolidine-2
carboxylic acid) is directed at SAP specifically. CPHPC
binds to circulating SAP to form complexes that are
rapidly cleared by the liver [52]. In 31 patients with sys-
temic amyloidosis, subcutaneous CPHPC resulted in sig-
nificant decreases in the circulating SAP concentration;
however, tissue-bound SAP remained present in amyloid
deposits in tissues [53,54]. To target residual bound
SAP, anti SAP immunoglobulin-G (IgG) antibodies have
been generated [55]. In a murine system, transgenic
mice with human SAP and amyloid deposition in the
liver and spleen were treated first with CPHPC to elimi-
nate circulating human SAP followed by a single dose of
the anti-SAP antibody. By 24 hours following anti-SAP
IgG injection, visceral amyloid deposits were densely
infiltrated by inflammatory cells and by 7 days almost
all amyloid in the liver and spleen was destroyed. Amy-
loid clearance was largely complete by day 16 following
treatment and the normal architecture of liver and
spleen were restored [55]. Based on these studies,
CPHPC in combination with a fully humanized mono-
clonal anti-human SAP is currently being studied in
early phase clinical trials in Europe and may be applic-
able to all forms of amyloid.
Targeting the kappa and lambda light chain has also
been explored, and investigators at the University of
Tennessee have generated monoclonal antibodies by
immunizing mice with human light chain fibrils [56].
Interestingly, these antibodies recognize an epitope com-
mon to the beta pleated sheet structure of AL and other
amyloid proteins and may also have broader therapeutic
implications. Using an in-vivo animal model in which
human amyloidomas were produced in mice [56], and
radioactively labeled monoclonal antibodies localized
only to the tumor [57]. Subsequent studies showed that
the amyloidomas could rapidly be eliminated following
antibody administration [56]. One prototypic antibody,
IgG1k mAb 11-1F4, has been chimerized and is being
studied in a phase I/II study.
Immunotherapeutic approaches directed at the patho-
logic plasma cell are also being investigated. Studies
exploring the expression of cancer testis antigen (CTA)
on the plasma cells of patients with multiple myeloma
have stimulated similar research in AL amyloidosis.
C T A sa r eac l a s so fp r o t e i n sf o u n do nav a r i e t yo f
tumor cells but are otherwise restricted to testicular
germ cells and the placenta. The pathologic plasma cells
of multiple myeloma commonly express two specific CT
antigens, CT7 and MAGEA3 as demonstrated by immu-
nohistochemistry and RT-PCR and expression is
increased with advanced disease and higher degree of
plasma cell proliferation [58]. An antigen-specific cancer
immunotherapeutic combining recombinant MAGEA3
and an adjuvant has been developed and is in phase I
testing as post transplant consolidation in patients with
multiple myeloma. In AL amyloidosis, CT-7 expression
has been confirmed by immunohistochemistry in 60% of
patients studied [59]. CT-7 DNA and dendritic cell
(DC) vaccines are currently being developed and may
have promise for AL amyloid patients in the future.
The graft versus tumor effect that follows allogeneic
SCT is the most potent form of immunotherapy. Due to
amyloid related organ disease, toxicity of allogeneic SCT
can be substantial in AL patients [60]. However, the
success of this strategy in small numbers of patients
provides proof of principal that antitumor immune
effects may be important in AL patients [61-64]. A
review of 19 patients from the European Group for
Blood and Marrow Transplantation (EBMT) registry
reported one year OS and progression free survival
(PFS) as 60% and 53% respectively; at two years OS and
PFS were 52% and 46%, respectively [60]. A high TRM
of 40% was seen among all patients. Favorable perfor-
mance status, non-total body irradiation (TBI) - based
conditioning and the use of a reduced intensity regimen
were associated with improved outcomes. Patients trea-
ted with ex-vivo T-cell depletion had worse outcomes
compared to those treated with conventional grafts and
chronic graft versus host disease (GVHD) was observed
in the 5 of 7 evaluable patients who achieved a CR sug-
gesting an immunologic graft versus disease effect [60].
As with other treatments for AL amyloidosis, CR was
the main predictor of long term survival. Transplant
physicians are now charged with developing a well toler-
ated conditioning regimen to be combined with T-cell
manipulation, perhaps with the early introduction of
donor lymphocyte infusion in order to spare toxicity
and take advantage of a graft versus tumor affect in
patients with relapsed disease.
Conclusion
AL amyloidosis is a rare and potentially devastating dis-
ease that is likely under diagnosed. Advances in diagnos-
tic techniques and the use of cardiac biomarkers for
staging and free light chains to grade response have
improved care. For newly diagnosed patients with stage
I and II disease, aggressive treatment with HDM/SCT is
warranted because the approach is effective and results
in rapid hematologic responses; however, the toxicity of
this approach must be appreciated and a risk adapted
dosing should be adopted. Treatment for transplant
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advanced organ disease involvement is evolving and may
include the use of oral alkylating agents, corticosteroids
as well as novel agents in different combinations. The
proteasome inhibitor bortezomib has single agent activ-
ity in Al amyloidosis and when combined with che-
motherapy or administered following SCT, has resulted
in the highest response rates to date. Second and third
generation proteasome inhibitors are being investigated.
For relapsed and refractory patients, newer agents and
novel approaches using immunotherapy are being
explored.
Referral to a center of excellence experienced in car-
ing for patients with amyloid related organ dysfunction
is essential because patients often require the expertise
of a multidisciplinary team. Although hematologic
responses have become more frequent, organ improve-
ment evolves over months to years so management of
patients requires vigilant attention to supportive thera-
pies. In addition, access to investigational approaches is
likely to be available only at these centers. While the
explosion of novel agents with activity in multiple mye-
loma holds promise for the care of patients with AL
amyloidosis, a commitment specifically to the clinical
investigation of treatment for AL amyloidosis is critical
in order to improve patient outcomes.
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